- Home
- SSBK vs ETON Comparison
SSBK vs ETON Comparison
Compare SSBK & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- ETON
- Stock Information
- Founded
- SSBK 2007
- ETON 2017
- Country
- SSBK United States
- ETON United States
- Employees
- SSBK N/A
- ETON N/A
- Industry
- SSBK Commercial Banks
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- ETON Health Care
- Exchange
- SSBK Nasdaq
- ETON Nasdaq
- Market Cap
- SSBK 330.0M
- ETON 329.8M
- IPO Year
- SSBK 2021
- ETON 2018
- Fundamental
- Price
- SSBK $32.30
- ETON $14.78
- Analyst Decision
- SSBK Buy
- ETON Strong Buy
- Analyst Count
- SSBK 1
- ETON 3
- Target Price
- SSBK $36.00
- ETON $27.67
- AVG Volume (30 Days)
- SSBK 13.7K
- ETON 248.9K
- Earning Date
- SSBK 04-21-2025
- ETON 03-18-2025
- Dividend Yield
- SSBK 1.09%
- ETON N/A
- EPS Growth
- SSBK 3.77
- ETON N/A
- EPS
- SSBK 3.67
- ETON N/A
- Revenue
- SSBK $94,140,000.00
- ETON $39,011,000.00
- Revenue This Year
- SSBK $19.13
- ETON $107.69
- Revenue Next Year
- SSBK $7.78
- ETON $65.50
- P/E Ratio
- SSBK $8.72
- ETON N/A
- Revenue Growth
- SSBK 13.56
- ETON 23.29
- 52 Week Low
- SSBK $22.13
- ETON $3.03
- 52 Week High
- SSBK $39.16
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- SSBK 50.63
- ETON 47.81
- Support Level
- SSBK $31.49
- ETON $12.73
- Resistance Level
- SSBK $33.14
- ETON $15.73
- Average True Range (ATR)
- SSBK 0.83
- ETON 0.96
- MACD
- SSBK 0.13
- ETON 0.03
- Stochastic Oscillator
- SSBK 62.83
- ETON 63.66
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.